



Leigh Syndrome with *MT-ND5* Mutation and Hypertrophic Cardiomyopathy

Ji-Hoon Na¹ · Young-Mock Lee¹

Received: 14 May 2023 / Accepted: 1 June 2023 / Published online: 15 June 2023
© The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation 2023

To the Editor: Leigh syndrome (LS) is the most common mitochondrial disease occurring during childhood. The primary symptoms of LS are neurological, such as developmental regression, epilepsy, and gait disturbance. Among them, recent reports suggest significant associations between pathogenic variant in NADH dehydrogenase 5 (*MT-ND5*) and the presence of cardiomyopathy in LS [1, 2]. Here we report a case series that investigate the relationship between cardiac symptoms and *MT-ND5*-associated LS identified in infants at a single tertiary hospital in South Korea.

We used mitochondrial DNA whole genome sequencing to determine a genetic diagnosis in 31 patients with clinical LS. Four patients with the *MT-ND5* m.13513G>A variants were identified. The median mutant load was 66.7% (55.5–71.6%). All patients with pathogenic *MT-ND5* variants underwent electrocardiography (ECG) and echocardiography at the time of diagnosis. Hypertrophic cardiomyopathy was diagnosed by identifying features such as left ventricular hypertrophy and abnormal movement of the cardiac valves on M-mode imaging or two-dimensional echocardiography. ECG showed biventricular and left ventricular hypertrophy in three and one patients, respectively. In addition, hypertrophic cardiomyopathy in all four patients was revealed on echocardiography. Active respiratory support was required in two patients and three patients required respiratory support and oxygen dependency.

Cardiac involvement in *MT-ND5*-associated LS has been occasionally reported, including the presence of Wolff–Parkinson–White Syndrome and paroxysmal supraventricular tachycardia [3]. The purported mechanism underlying mitochondrial hypertrophic cardiomyopathy is a combination of elevated reactive oxygen species, limited antioxidant activity, impaired mitophagic clearance, and mitochondrial morphologic abnormalities of genetic origin. Thus, hypertrophic cardiomyopathy may be a characteristic

phenotype of *MT-ND5*-associated LS. Studies of the mechanism of mitochondrial dysfunction in the myocardium should be the basis for the development of new LS treatments [4]. Here, our findings provide additional supportive data to strengthen the ongoing foundation of genotype–phenotype correlations in *MT-ND5*-associated LS.

Acknowledgements The authors are grateful to all staff members, doctors, and statistical consultants who were involved in this study.

Funding This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: 2018-31-0425/HI18C1166020018, 2018-31-1061/HI18C1166020019 & 2019-31-1183/HI18C1166020020) and a faculty research grant of Yonsei University College of Medicine (grant number: 6-2021-0123).

Declarations

Conflict of Interest None.

References

1. Sofou K, de Coo IFM, Ostergaard E, et al. Phenotype-genotype correlations in Leigh syndrome: new insights from a multicentre study of 96 patients. *J Med Genet.* 2018;55:21–7.
2. Na JH, Lee YM. Genotype-phenotype analysis of *MT-ATP6*-associated Leigh syndrome. *Acta Neurol Scand.* 2022;145:414–22.
3. Brecht M, Richardson M, Taranath A, Grist S, Thorburn D, Bratkovic D. Leigh syndrome caused by the *MT-ND5* m.13513G > A mutation: a case presenting with WPW-like conduction defect, cardiomyopathy, hypertension and hyponatraemia. *JIMD Rep.* 2015;19:95–100.
4. Ranjbarvaziri S, Kooiker KB, Ellenberger M, et al. Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy. *Circulation.* 2021;144:1714–31.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Young-Mock Lee
ymleemd@yuhs.ac

¹ Department of Pediatrics, Yonsei University College of Medicine, Gangnam Severance Hospital, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea